Sun Set to Buy Ranbaxy, Turn India’s Biggest Pharma Firm

In one of the largest domestic acquisitions, Sun Pharmaceutical Industries Ltd, on Monday agreed to buy Ranbaxy Laboratories Ltd for $3.2 billion.

Published: 08th April 2014 08:00 AM  |   Last Updated: 08th April 2014 08:07 AM   |  A+A-


In one of the largest domestic acquisitions, Sun Pharmaceutical Industries Ltd, on Monday agreed to buy Ranbaxy Laboratories Ltd for $3.2 billion. Including Ranbaxy’s debt, the overall transaction stands at nearly $4 billion. The all-stock deal is one of the biggest transactions not only in the Indian pharma sector but also across the Asia-Pacific region. The combined entity will emerge as the world’s 5th largest generics producer.

The deal catapults Sun as the biggest generics firm by sales in India, with an estimated combined revenue of $4.2 billion. Sun is currently India’s largest drug maker by market value.

As per the agreement, Ranbaxy shareholders will get 0.8 of a Sun Pharma share for each Ranbaxy share they own. The deal is expected to close by the end of 2014.

For Ranbaxy’s existing owner Daiichi Sankyo, the transaction comes as a major breather with the Japanese major facing intense criticism from the US health regulator over Ranbaxy’s manufacturing processes at its India plants.

Daiichi acquired a 63.9 per cent stake in Ranbaxy from its erstwhile owners — Malvinder and Shivinder Singh — for $4.2 billion. With the acquisition, Daiichi will have about 9 per cent stake in Sun valued at $2 billion and will be the second largest shareholder in Sun.

“This transaction helps us transition to our long-held ambition of becoming a successful Indian company in the global pharmaceutical space,” said Dilip Shanghvi, MD, Sun Pharma. According to him, the combined entity would focus on fixing manufacturing quality issues at Ranbaxy in order to resume exports.

Sun expects the acquisition to be accretive to earnings per share in the first full year and expects revenues of $250 million and operating synergies by the third year. 

Stay up to date on all the latest Business news with The New Indian Express App. Download now


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp